Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 15/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393938 | 0.97 | CCR6 (0.47) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL4377019 | 0.88 | TRPV4 (0.36) | CCR6CCNA2CDK2 | |
| SCHEMBL4395263 | 0.87 | POLB (0.41) | CCR6CCNA2CDK2 | |
| SCHEMBL8217724 | 0.81 | CCR6 (0.46) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL4382730 | 0.79 | MEN1 (0.42) | CCR6GPR6 | |
| SCHEMBL4380375 | 0.72 | CCR6 (0.45) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL4395449 | 0.70 | CCR6 (0.49) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL8210456 | 0.68 | CCR6 (0.53) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL8222252 | 0.66 | KMT2A (0.53) | — | |
| SCHEMBL4395257 | 0.66 | CYP11B1 (0.43) | GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CCR6 2413/4885CCNA2 2430/4885CDK2 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.